Sara Brenner's federal-government biography names a path from Cleveland Clinic radiology, through Albany Nanotech, into the FDA's Center for Devices, into the Acting Commissioner's chair when Trump returned to office, and now into the principal-deputy line authority at CDC. [1] The Apr 30 paper carried the appointment as a contradiction of Trump's mid-April vaccine-skeptic pledge. The May 1 question is what staffs the office.

The office is small. The principal-deputy historically runs day-to-day editorial control of the Morbidity and Mortality Weekly Report, the publication queue that translates surveillance into policy. The line authority over MMWR sits with the principal-deputy regardless of who chairs ACIP or who answers calls from the secretary's office. Trade-press tracker Alexander Gaffney named Brenner's reported senior-HHS role as the FDA's loss before the announcement landed. [2]

The HHS coordination question runs the other way. The agency Robert F. Kennedy Jr. inherited has rebuilt its senior tier around the MAHA-mother network the Times profile traced; CIDRAP has documented the December hep-B vote, the unpublished Covid-vaccine MMWR, and the routine immunization schedule as the three artifacts now routing through the same publications office. [3] The FDA-to-CDC pivot looks small on an org chart and large on the publications schedule.

Senator Patty Murray's office indicated Thursday it would seek a closed-door briefing before any next confirmation cycle. The American Medical Association said its review committee would weigh in by mid-May. [4] On May 1, the principal-deputy office is staffed; what it ships, the country reads. The first Friday under the new line authority arrived without a staff list.

-- NORA WHITFIELD, Chicago